JCXH 108
Alternative Names: JCXH-108Latest Information Update: 28 Aug 2024
At a glance
- Originator Immorna
- Class Respiratory syncytial virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 27 Aug 2024 Pharmacodynamics data from a preclinical studies in Respiratory syncytial virus infections released by Immorna Biotherapeutics
- 22 Aug 2024 Immorna Biotherapeutics plans a phase I trial for Respiratory syncytial virus (Prevention) in August 2024 (IM) (NCT06564194)
- 20 Feb 2023 Preclinical trials in Respiratory syncytial virus infections (Prevention) in China (Parenteral) (Immorna pipeline; February 2023)